Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 7/20 | 0.35 |
| ▸ | FLT1 | P17948 | 7/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | FLT4 | P35916 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25210834 | 0.81 | MKNK1 (0.35) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL25215083 | 0.78 | PLAU (0.40) | PLAUHTTHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL25237933 | 0.71 | FEN1 (0.32) | — | |
| SCHEMBL25208533 | 0.70 | MKNK2 (0.40) | EGFR | |
| SCHEMBL25215031 | 0.70 | NOS3 (0.31) | SMN1; SMN2 | |
| SCHEMBL18172021 | 0.69 | THRB (0.44) | HTTHPGDALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL25257796 | 0.69 | NPC1 (0.42) | HPGDALDH1A1SMN1; SMN2KDM4EKMT2A | |
| Hydrochloric Acid SCHEMBL18172006 | 0.68 | THRB (0.43) | HTTHPGDALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL595219 | 0.67 | LMNA (0.39) | HTTHPGDALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL22072959 | 0.67 | PLAU (0.40) | PLAUHTTALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509122-A2 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2025-02-19 | — | — | EP | disclosed |
| EP-4188930-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AG (DE) | 2024-10-23 | — | — | EP | disclosed |
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-07 | — | — | US | disclosed |
| EP-4188930-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391769-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THERAPEUTIC USES THEREOF | CYP11B2, SDHA, UGT2B7 | PLAU 1013/4885HTT 378/4885HPGD 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.